Clinical Trials Logo
  1. Home
  2. Idiopathic Pulmonary Fibrosis
  3. NCT02827734
  4. Details
NCT02827734 Clinical Trial

Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:
Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02827734
Other study ID # MBW-ILD
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 2015
Est. completion date December 2020

Study information
Verified date March 2020
Source Universitätsmedizin Mannheim
Contact Frederik Trinkmann, Dr.
Phone +496213833879
Email frederik.trinkmann@umm.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Current diagnostic tools used in interstitial lung disease (ILD) do not meet the challenges set by the complex pathophysiology of this heterogenous group. The investigators therefore aimed to evaluate novel or not widely used diagnostic approaches for the detection and therapeutic monitoring of patients with various ILDs.

Recruitment information / eligibility
Status Recruiting
Enrollment 50
Est. completion date December 2020
Est. primary completion date December 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- known or suspected interstitial lung disease

Exclusion Criteria:

- pregnancy

- inability to participate

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• multiple breath washout tests

• impulse oscillometry

• body plethysmography

Locations
Country Name City State
Germany Universitätsmedizin Mannheim Mannheim Deutschland

Sponsors (1)
Lead Sponsor Collaborator
Universitätsmedizin Mannheim

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary lung clearance index (LCI) as determined by multiple breath washout 30 minutes
Primary airway resistance and reactance (R5, X5, R-D5-20) as determined by impulse oscillometry 30 minutes
Secondary repeatability of lung clearance index (LCI) 30 minutes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants Phase 1
Active, not recruiting NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT03865927 - GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979430 - Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study N/A
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Not yet recruiting NCT06241560 - A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood Phase 2
Terminated NCT04419558 - Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 3
Completed NCT03725852 - A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Terminated NCT03573505 - An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04148157 - Quality of Life in IPF - Patient and Physician Perceptions
Completed NCT03222648 - Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis N/A
Not yet recruiting NCT06422884 - A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) Phase 2
Completed NCT02268981 - Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) N/A
Completed NCT02257177 - RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Phase 1/Phase 2
Withdrawn NCT01524068 - A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 2
Enrolling by invitation NCT01382368 - Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Phase 4
Completed NCT01110694 - Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Completed NCT01199887 - Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis Phase 1
Active, not recruiting NCT02951416 - Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3